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Diastolic Function in Heart Failure
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Presentation Hour: 1:00 p.m.-2:00 p.m.
1087-103 Plasma Metalloproteinase Levels Are Correlated With 
Natriuretic Peptide and Endothelin-1 Levels in Patients 
With Heart Failure
Raymond T. Yan, Andrew T. Yan, Himali R. Gunasinghe, Peter P. Liu, Francis G. Spinale, 
Robert S. McKelvie, McMaster University, Hamilton, ON, Canada, University of Toronto, 
Toronto, ON, Canada
Background: Several neurohormones can activate matrix metalloproteinases (MMPs)
which regulate extracellular matrix turnover and left ventricular (LV) geometry in the fail-
ing myocardium. However, the relationships between the various neurohormonal and
MMP systems in heart failure (HF) have not been elucidated.
Methods: Patients with symptomatic HF and LV ejection fraction <0.40 were randomized
in the RESOLVD trial to various combination regimens of candesartan, enalapril, and
metoprolol. In this substudy, plasma MMP-2, MMP-9, tissue inhibitor of metalloprotein-
ase-1 (TIMP-1), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), angio-
tensin-II, aldosterone, and endothelin-1 were measured by ELISA in 184 patients at
baseline. Epinephrine and norepinephrine were measured by HPLC.
Results: The relationships between plasma MMP and neurohormone levels are tabu-
lated below. 
*P<0.001
**P<0.01
†P<0.05
Conclusion: Increased plasma MMP-2 and TIMP-1 levels were related to elevated levels
of ANP, BNP and endothelin-1. In contrast, the renin-angiotensin-aldosterone and the
sympathetic nervous systems, both of which have been historically associated with pro-
moting fibrosis, did not correlate with MMP levels. Therefore, MMP and TIMP levels
appear to be differentially regulated by certain bioactive signals, rather than a non-spe-
cific global induction in HF. These new findings suggest that these proteolytic pathways
can be modified through selective pharmacological targets.
1087-104 Pioglitazone Modulates Collagen Synthesis in 
Fibroblasts in Response to Angiotensin II
Kui Chen, Dayuan Li, Xing Jiang Zhang, Jawahar L. Mehta, University of Arkansas for 
Medical Sciences, Little Rock, AR, Central Arkansas Veterans Healthcare System, Little 
Rock, AR
Background and Objectives: Angiotensin II (Ang II) and free radicals are potent media-
tors of ischemic cardiac dysfunction. Fibroblast growth and activity (collagen formation)
characterize this process in response to Ang II and free radicals. Recent studies suggest
that PPAR-γ ligands have the potential to modulate the process of acute ischemic injury
and its long-term consequences. This study examined the modulation of fibroblast activa-
tion in response to Ang II by the PPAR-γ ligand pioglitazone.
Methods and Results: Cultured rat cardiac fibroblasts were treated with Ang II (10-8 to
10–6 M) for 12 hrs. Parallel sets of fibroblasts were pretreated with pioglitazone (10-6 M)
before exposure to Ang II (10-7 M). Treatment with Ang II resulted in increased collagen-1
and reduced MMP-1 protein expression in cardiac fibroblasts (both P<0.01). Ang II treat-
ment also reduced protein kinase B (PKB)/Akt expression. Pretreatment of cells with
pioglitazone completely blocked the decreased PKB/Akt expression in Ang II–treated
cells, and simultaneously inhibited the effects of Ang II on collagen and MMP expression
(all P<0.01 vs. Ang II alone).
Conclusion: This study shows that Ang II enhances collagen and reduces MMP-1 pro-
tein expression in fibroblasts. Importantly, pioglitazone blocks these effects of Ang II,
most likely by PKB/Akt activity in fibroblasts.
1087-105 Synergistic Effects of the Addition of Candesartan to 
Enalapril on Myocardial Fibrosis and Left Ventricular 
Diastolic Function in Dogs With Heart Failure
Kaoru Funabiki, Katsuya Onishi, Kaoru Dohi, Takafumi Koji, Masaki Tanabe, Tetsuya 
Kitamura, Masaaki Ito, Takeshi Nakano, Mie University School of Medicine, Tsu, Japan
Backgrounds: Angiotensin II (AngII) type 1 receptor blocker, candesartan reduced rele-
vant cardiovascular events when added to ACE inhibitors in patients with congestive
heart failure (CHF). Candesartan prevents myocardial fibrosis due to the effective inhibi-
tion of AngII in animals with non-ACE pathway, while ACE inhibitor acts on myocardial
fibrosis partly through the bradykinin-mediated mechanism as well as the inhibition of
AngII. Therefore, we hypothesized that the addition of candesartan to enalapril synergis-
tically prevented myocardial fibrosis and improved left ventricular (LV) diastolic function to
the greater extent than each drug alone in CHF. Methods: Twenty-eight dogs were
assigned to the following treatment protocols on the 8th day of a 4-week rapid pacing: (A)
rapid ventricular pacing (240 bpm, n=7), (B) enalapril (1.9 mg/kg/day) and pacing (n=7),
(C) candesartan (1.5 mg/kg/day) and pacing (n=7), (D) combined enalapril (0.95 mg/kg/
day) and candesartan (0.75 mg/kg/day) and pacing (n=7).
Results: Although there was no difference in myocardial AngII levels among all groups,
concomitant use of enalapril and candesartan significantly decreased LV end-diastolic
pressure and LV stiffness estimated by LV pressure-volume plane to the greater extent
than each drug alone. Furthermore, it suppressed the expression of the collagen-type 1
and 3 mRNA (p<0.05) and decreased the values of LV collagen volume fraction evalu-
ated with picrosirius red stain (A 6±1, B 4±1*, C 3±1*†, D 2±1*†‡ %, respectively; *p<0.05
vs. A, †p<0.05 vs. B, ‡p<0.05 vs. C). Conclusion: Concomitant use of enalapril and can-
desartan synergistically prevented LV fibrosis and improved LV diastolic function during
the development of CHF. Thus, the addition of candesartan to ACE inhibitor may become
an important strategy for the prevention of cardiac remodeling.
1087-106 Early Serum Levels of Tissue Inhibitor of 
Metalloproteinases-1 but Not Matrix Metalloproteinase-1 
Are Associated With Cardiovascular Death After 
Complicated Myocardial Infarction
Cord A. Manhenke, Stein Ørn, Faiez Zannad, Torbjørn Aarsaland, Kenneth Dickstein, 
The OPTIMAAL Trial Study Group, Rogaland Central Hospital, Stavanger, Norway
Background: The complex process of early remodeling in acute myocardial infarction
(AMI) involves activation of matrix metalloproteinases (MMPs). We related increased
serum levels of MMP-1 and type1-tissue inhibitor of matrix metalloproteinases (TIMP-1)
to adjudicated cardiovascular mortality in patients following complicated AMI.
Methods: Serum from 233 patients in the OPTIMAAL trial which included patients follow-
ing AMI with heart failure and/or left ventricular dysfunction was sampled at randomiza-
tion (mean 3 days after index MI).
Results: Mean MMP-1 and TIMP-1 for all patients were 6.5 (+ 6.6) and 1610 (+ 623) ng/
ml respectively. During a mean follow-up of 2.6 years cardiovascular death occurred in 29
patients. Non-survivors had significantly higher serum levels of TIMP-1 but not MMP-1
compared to survivors during follow-up (mean 1960 (+749) vs. 1660 (+588) ng/l, p=.003
for TIMP-1 and mean 8.2 (+7.9) vs. 6.2 (+6.4) ng/ml, p=.097 for MMP-1). Patients above
and below mean TIMP-1 values had a mortality rate of 18.1% and 9.5% respectively (log
rank p=.031) (fig.).
Conclusion: Increased levels of TIMP-1 are associated with increased cardiovascular
mortality following high risk AMI. As TIMP-1 also is upregulated by free MMPs other than
MMP-1 this finding suggests that other MMP subtypes are activated during the acute
phase following complicated AMI. 
1087-107 Transforming Growth Factor Beta and Factor XIIIa Are 
Constituents of the Carcinoid Heart Endocardial Layer: 
A Study by Confocal Laser Microscopy
Bernhard Maisch, Dorgit Diepholz, Reinhard Funck, Andreas Wilke, Rudi Arnold, 
Philipps-University, Marburg, Germany
The detailed composition of the carcinoid right ventricular endocardial layer and the
pathogenesis are still unresolved. One common explanation is that fibrosis occurs as a
consequence to microlesions induced by high levels of circulating serotonin and bradyki-
nin.
Methods: The right ventricular endomyocardial biopsies of 7 patients (5 female, mean
age 43,9 + 11,4 y) with established carcinoid syndrome and right ventricular disease
Kendall’s tau correlation MMP-2 MMP-9 TIMP-1
ANP 0.26 * 0.060 0.21 *
BNP 0.21 * 0.030 0.14 **
Angiotensin-II -0.084 0.067 -0.079
Aldosterone 0.005 0.096 -0.061
Epinephrine 0.067 0.025 0.005
Norepinephrine 0.041 -0.006 0.047
Endothelin-1 0.11 † 0.010 0.15 **
